Grant Submission Information
The SAS Foundation for Cancer Research will award a maximum of $100,000 annually, to seek out potential cures for cancer or to alleviate the impact of cancer. Agencies may submit only one proposal per year.
​
Proposals must be received to the address noted by Friday, November 1st, 2024. Proposals postmarked but not received by this date cannot be considered. Early submission is recommended but no required. Decisions will be announced approximately six to eight weeks after submission.
​
For complete guidelines, instructions and forms, click here
​
​
Past Grant Awardees
2022
To Roswell Park Alliance Foundation (Grantee) for the proposal entitled – Deciphering the drug resistance mechanism of triple-negative breast cancer against doxorubicin by proteome-wide overexpression perturbation. This grant, #HHS-0016-22SF, is being made in response to your organization’s original proposal submitted in October 2022. The grant period for this award is January 1, 2023 through December 31, 2023.
2021
To Roswell Park Alliance Foundation (Grantee) for the proposal entitled – Exploring the role of HNF1A in tumor growth and microenvironment dynamics in pancreatic ductal adenocarcinoma. This grant, #HHS-0015-21SF, is being made in response to your organization’s original proposal submitted in October 2021. The grant period for this award is January 1, 2022 through December 31, 2022.
2020
To Lustgarten Foundation (Grantee) for the proposal entitled – Translational Convergence Program Dedicated Laboratory. This grant, #HHS-0013-20SF, is being made in response to your organization’s original proposal submitted in October 2020. The grant period for this award is January 1, 2021 through December 31, 2021.
​
2020
To Roswell Park Alliance Foundation (Grantee) for the proposal entitled – Comparison of intermittent fasting with continuous caloric reduction in black adults of faith. This grant, #HHS-0014-20SF, is being made in response to your organization’s original proposal submitted in October 2020. The grant period for this award is January 1, 2021 through December 31, 2021.
2019
​To Lustgarten Foundation (Grantee) for the proposal entitled – Personalized Medicine: Organoids & Pancreatic Adenocarcinoma Signature Stratification (PASS). This grant, #HHS-0012-19SF, is being made in response to your organization’s original proposal submitted in October 2019. The grant period for this award is January 1, 2020 through December 31, 2020.
2019
To Children’s Hospital of Philadelphia (Grantee) for the proposal entitled – Precision Medicine Approaches to Target Bcl2 Survival Proteins for Highly Lethal Neuroblastoma. This grant, #HHS-0011-19SF, is being made in response to your organization’s original proposal submitted in October 2019. The grant period for this award is January 1, 2020 through December 31, 2020.
2019
To Roswell Park Alliance Foundation (Grantee) for the proposal entitled – Epigenetic/Immunotherapy Approaches for Relapsed/Refractory Pediatric Solid Tumors. This grant, #HHS-0010-19SF, is being made in response to your organization’s original proposal submitted in October 2019. The grant period for this award is January 1, 2020 through December 31, 2020.
​
2017
To Roswell Park Alliance Foundation/Roswell Park Cancer Institute (Grantee) for the Prevention of prostate cancer progression and therapy-induced muscle loss. The grant period for this award is December 15, 2017 through December 31, 2018.
2016
To University of Notre Dame (Grantee) for the Characterizing the role of Aquaporin-7 in the breast cancer metabolic landscape. The grant period for this award is January 1, 2017 through December 31, 2017.
2016
To Albert Einstein College of Medicine (Grantee) for the Targeting the PRMT5 Arginine Methyltransferase: An Achilles’ Heel for Many Cancers. The grant period for this award is January 1, 2017 through December 31, 2017.
2015
To Roswell Park Alliance Foundation/Roswell Park Cancer Institute (Grantee) for the Inhibiting androgen deprivation therapy-induced sarcopenia in prostate cancer (prevention of castration-induced muscle loss in prostate cancer). The grant period for this award is November 25, 2015 through December 31, 2016.
2014
To Albert Einstein College of Medicine of Yeshiva University (Grantee) for the “Characterizing Magmas regulation and determining its role in energy metabolism and cancer treatment”. The grant period for this award is March 15, 2014 through December 2015.
2012
To Children's Hospital of Philadelphia (Grantee) for the "A Novel Approach to Enhance and redirect the anti-Leukemia Properties of human Invariant Natural Killer T cells", to develop new ways to stimulate the immune system to more effectively treat different types of cancer. The grant period for this award is November 9, 2012 through December 2014.
2011
To Yale School of Medicine (Grantee) for the small molecule Magmas inhibitor (SMMI) pharmacokinests, and evaluation as a cancer treatment and imaging agent. The grant period for this award is November 23, 2011 through December 2013.
2010
To Roswell Park Alliance Foundation (Grantee) for the identification of genes essential for mammary, pancreatic, epithelia, and melanocytes as potential targets for cancer therapy. The grant period for this award is December 3, 2010 through December 2012.
2009
To Roswell Park Alliance Foundation (Grantee) for MicroRNA expression profiling recurrence after resection of stage 1 Non-Small Cell Lung Cancer Project. Grant period for this award is December 18, 2009 through December 2011.